fondaparinux Side Effects
Also known as: Arixtra
Analysis of 7,980 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
7,980
Death-Related
1,436
18.0% of reports
Hospitalizations
4,235
53.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,436 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 294 |
| CEREBRAL HAEMORRHAGE | 124 |
| PULMONARY EMBOLISM | 117 |
| ANAEMIA | 84 |
| HAEMORRHAGE | 78 |
| SHOCK HAEMORRHAGIC | 76 |
| HAEMATOMA | 69 |
| SEPSIS | 69 |
| OFF LABEL USE | 63 |
| COMA | 62 |
| THROMBOCYTOPENIA | 61 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 57 |
| CARDIAC ARREST | 53 |
| RENAL FAILURE | 49 |
| HYPOTENSION | 48 |
| MALIGNANT NEOPLASM PROGRESSION | 48 |
| DYSPNOEA | 46 |
| GASTROINTESTINAL HAEMORRHAGE | 45 |
| FALL | 43 |
| PNEUMONIA | 43 |
Reactions in Hospitalization Reports
Top reactions in 4,235 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ANAEMIA | 476 |
| HAEMATOMA | 429 |
| PULMONARY EMBOLISM | 270 |
| HAEMOGLOBIN DECREASED | 221 |
| OFF LABEL USE | 221 |
| DYSPNOEA | 191 |
| DEEP VEIN THROMBOSIS | 190 |
| ABDOMINAL PAIN | 177 |
| MUSCLE HAEMORRHAGE | 172 |
| THROMBOCYTOPENIA | 169 |
| HAEMORRHAGE | 165 |
| VOMITING | 163 |
| PYREXIA | 162 |
| INCORRECT DRUG ADMINISTRATION DURATION | 159 |
| DIARRHOEA | 158 |
| NAUSEA | 149 |
| HYPOTENSION | 147 |
| THROMBOSIS | 142 |
| PAIN IN EXTREMITY | 139 |
| DRUG INEFFECTIVE | 135 |
Nearby — Related Medications
What the FAERS Data Reveals About fondaparinux Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 7,980 voluntary reports linked to fondaparinux and its brand equivalents (Arixtra), spanning 2004 through 2025. Of those, 1,436 (18.0%) listed death as an outcome and 4,235 (53.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 43% male; age distribution skews toward 75+, with 1,683 reports in that bracket. The single most reported reaction is anaemia with 610 submissions, followed by haematoma and pulmonary embolism.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.